Last reviewed · How we verify

NCT05094726

Effect of PBM on Functional Capacity and Fatigability in Post Covid-19 Elderly

Status unknown NA Last updated 26 October 2021
What this trial tests

NA trial testing photobiomodulation in Post Covid-19 Elderly in 100 participants. Status unknown.

Timeline
8 September 2021
Primary endpoint
30 October 2021
15 November 2021

Quick facts

Lead sponsorCairo University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment100
Start date8 September 2021
Primary completion30 October 2021
Estimated completion15 November 2021
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Cairo University

Who can join

Adults 60 to 75, any sex, with Post Covid-19 Elderly. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Participants had randomly divided into two equal groups. Group (A) which is the study group will receive photobiomodulation session two times per week for four weeks. Group (B) will be the control group that will receive placebo photobiomodulation two times per week for four weeks.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of photobiomodulation

Trials testing the same drug.

Other Cairo University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05094726.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing